Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxamine SCHEMBL4258100 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL34158 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL5172511 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL29763696 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL5172508 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL4258097 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL1043727 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL7786034 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL146117 | 0.98 | MEN1 (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 | |
| Methoxamine SCHEMBL9614282 | 0.98 | MEN1 (1.00) | ADRA1AADRA2ACYP2D6MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105675735-A | Breast cancer diagnostic marker combination and application and determination method thereof | 上海市第六人民医院 | 2016-06-15 | — | — | CN | claimed |
| CN-105503792-A | Method for synthesizing (Z)-2-(alpha-methoxyimino)furanylacetic acid ammonium | SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD | 2016-04-20 | — | — | CN | claimed |
| CN-105254603-A | Synthetic technology of furan ammonium salt | SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD | 2016-01-20 | — | — | CN | claimed |
| CN-105237433-A | Chemical preparation method of ribose oxime | UNIV TIANJIN POLYTECHNIC | 2016-01-13 | — | — | CN | claimed |
| CN-104478757-A | Method for safely preparing pure N, O-dimethylhydroxyamine hydrochloride | Yantai aodong chemical material co ltd | 2015-04-01 | — | — | CN | claimed |
| CN-104478740-A | Synthesis method of stable isotope-labeled beta receptor agonist type compound | SHANGHAI RES INST CHEMICAL IND | 2015-04-01 | — | — | CN | claimed |
| CN-103923081-A | Compound, preparation method and application thereof | WUHAN GUANGGU RENFU BIOLOG PHARMACEUTICAL CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-103709207-A | Chemical preparation method of L-ribose | UNIV TIANJIN POLYTECHNIC | 2014-04-09 | — | — | CN | claimed |
| CN-102690258-A | Nitrogenous heterocyclic-imide derivative and preparation method and purpose thereof | HUBEI BIOPESTICIDE ENGINEERING RES CT | 2012-09-26 | — | — | CN | claimed |
| CN-102516101-A | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | NORGINE EUROPE BV | 2012-06-27 | — | — | CN | claimed |
| CN-101357911-A | Method for synthesizing (z)-2-(alpha-methoxyimino)furan-ammonium acetate | JIANGSU ARYSTA QINGQUAN CHEMIC (CN) | 2009-02-04 | — | — | CN | claimed |
| CN-101279967-A | Medicinal composition of trimethyl xanthone-4-acetic acid for treating cancer and use thereof | WUHAN GRAND PHARMACEUTICAL GRO (CN) | 2008-10-08 | — | — | CN | claimed |
| CN-100374455-C | Treatment of nucleic acid | HUMAN GENETIC SIGNATURES CO LT (AU) | 2008-03-12 | — | — | CN | claimed |
| CN-101037401-A | High-purity methoxyamine methane sulfonic acid salt and preparation method thereof | YANTAI AODONG CHEMICAL MATERIA (CN) | 2007-09-19 | — | — | CN | claimed |
| CN-1962638-A | Kukoline compound with dextral C circle lacking of morphinan skeleton and its preparation method | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2007-05-16 | — | — | CN | claimed |
| CN-1784417-A | Treatment of nucleic acid | HUMAN GENETIC SIGNATURES PTY (AU) | 2006-06-07 | — | — | CN | claimed |
| CN-1179942-C | Sulfurous unsaturated oximinoethers with bactericidal activity and preparing process thereof | 湖南化工研究院 | 2004-12-15 | — | — | CN | claimed |
| CN-1401635-A | Sulfurous unsaturated oximinoethers with bactericidal activity and preparing process thereof | HUNAN CHEMICAL RES INST (CN) | 2003-03-12 | — | — | CN | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | ADRA1A 1404/4885ADRA2A 1483/4885CYP2D6 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.